Our data provide additional information on mechanisms whereby MR antagonists, such as spironolactone, protect against diabetes-associated vasculopathy and further support the idea that MR antagonists have beneficial vascular effects in diabetes-associated conditions. This evidence concerns the gene NR3C2 and vascular disorder.